(4) Dynamics SLO

Question 1

Almost all drugs interact with receptors. Which 3 DO NOT?
A. Mannitol (osmotic diuretic)
B. Antacids (neutralizing antacids)
C. Donepezil (used for Alzheimer’s)
D. All of the choices interact with a receptor
E. Chloestyramine (bile acid sequestrant)

Answer 1

Antacids (neutralizing antacids)
Chloestyramine (bile acid sequestrant)
Mannitol (osmotic diuretic)

Question 2

G-Protein Coupled Receptors (GPCR) differ from Ligand-Gated Ion Channels (LTIC) in that __?__
A. The GPCR uses a second messanger for signal transduction
B. Acetylcholine is always the neurotransmitter at GPCRs
C. Only the LGIC is ligand-activated
D. Acetylcholine is always the neurotransmitter at LGICs
E. The GPCR is ligand-activated

Answer 2

The GPCR uses a second messanger for signal transduction

Question 3

Genetic differences in expression of receptors may result in \_\_?\_\_ to a given drug.
A. 	Allergic reactions
B. 	Tolerance or insensitivity
C. 	Secondary diseases due to exposure
D. 	Toxic responses
E. 	All the above

Answer 3

Allergic reactions
Tolerance or insensitivity
Secondary diseases due to exposure
Toxic responses
***ALL***

Question 4

P-Glycoprotein (P-gp) is an ATP binding cassette pump important in __?__
A. Drug resistance in animals and bacteria
B. All the listed answers are correct
C. The blood brain barrier
D. Diseases, including Cystic fibrosis
E. The transport of metabolic products, nutrients and some drugs

Answer 4

The blood-brain barrier
Diseases, including Cystic Fibrosis
Drug resistance in animal & bacteria
Transport of metabolic products, nutrients & drugs
***ALL***

Question 5

Therapeutic index describes __?__
A. The plasma lab work required when giving a drug.
B. The margin of safety associated with the use of a particular drug.
C. How to give a drug.
D. The overall effectiveness of a drug.
E. Which drug works the best.

Answer 5

The margin of safety associated with the use of a particular drug.

Question 6

Which of the following is a (are) genetic difference(s) in metabolic enzymes that may result in ENHANCED ACTIVITY of a PRODRUG?
A. Having an inefficient form of the enzyme that metabolizes the Prodrug.
B. Having multiple copies of the gene coding for the enzyme that metabolizes the Prodrug or an efficient form of the enzyme.
C. Having no copies of the enzyme that metabolizes the Prodrug.
D. None of the listed answers is correct.
E. Having extra copies of the enzyme that breaks down the active form of the Prodrug.

Answer 6

Having multiple copies of the gene coding for the enzyme that metabolizes the Prodrug or an efficient form of the enzyme.

Question 7

Which of the following is a genetic difference that predisposes a person to drug-induced hemolytic anemia?
A. Competition for plasma protein binding sites
B. Induction of Phase 2 enzymes
C. Cystic fibrosis
D. G6PD deficiency
E. None of the listed answers is correct.

Answer 7

G6PD deficiency

Question 8

Genetic differences in the expression of metabolic enzymes, such that someone has multiple copies of a gene coding for a particular enzyme, may result in __?__ following administration of a drug metabolized by that enzyme (as long as its not a Prodrug).
A. No effect on the activity (of the drug)
B. Reduced activity (of the drug)
C. Increased risk of adverse effects (due to the drug)
D. Improved therapeutics
E. Enhanced activity (of the drug)

Answer 8

Reduced activity (of the drug)

Question 9

Ligands are "things" that \_\_?\_\_
A. 	Induce the synthesis of proteins
B. 	Are sold as drugs
C. 	Create new effects or processes
D. 	Are built into receptors
E. 	Bind to receptors

Answer 9

Bind to receptors